Alantolactone and Temozolomide Combination Targets Glioblastoma Stemness, Lipid Metabolism

Navigating the Glioblastoma Challenge

Glioblastoma, the most common and aggressive primary malignant brain tumor in adults, continues to present significant therapeutic hurdles [1, 2]. Despite a multimodal treatment approach that includes maximal safe surgical resection, radiotherapy, and temozolomide chemotherapy, patient prognosis remains poor, with a median overall survival typically under two years [3, 4, 5]. The inherent resistance of glioblastoma to standard chemotherapy and its high rate of recurrence are largely attributed to factors such as tumor heterogeneity, the presence of glioblastoma stem-like cells, and adaptive metabolic pathways [1, 6]. While temozolomide is a cornerstone of therapy, particularly for patients with MGMT promoter methylation, its efficacy is often limited by these complex biological mechanisms, creating an urgent need for more effective therapeutic strategies [7, 8, 9, 1, 2].

Investigating a Dual-Targeting Strategy for Glioblastoma

To address the persistent challenges of therapeutic resistance and recurrence in glioblastoma (GBM), a recent study explored the potential of a combination therapy. The investigation focused on the combined effects of alantolactone (ALT), a plant-derived compound, and the standard chemotherapeutic agent temozolomide (TMZ). Researchers hypothesized that a dual-pronged attack targeting tumor stemness, lipid metabolism, and the Hippo signaling pathway could yield a synergistic anti-tumor effect. The Hippo pathway, a critical regulator of cell proliferation and organ size, is increasingly recognized for its role in cancer biology.

To test this hypothesis, the study employed a two-phase approach. Initially, experiments were conducted in vitro using two human GBM cell lines, U87 and U251, which were treated with ALT and TMZ both individually and in combination. This allowed for a direct comparison of their effects on cancer cell biology. Subsequently, the investigation moved to an in vivo setting, where a xenograft mouse model was established by implanting human GBM cells into mice. This step was crucial for evaluating the combination's efficacy in a living system, providing a more clinically relevant assessment of its potential to suppress tumor growth.

Synergistic Effects on Cell Viability and Stemness Markers

The initial in vitro experiments confirmed that both alantolactone (ALT) and temozolomide (TMZ), when used alone, inhibited glioblastoma (GBM) cell proliferation in a dose-dependent manner. Cell viability was quantified using the CCK-8 assay, a standard colorimetric method that measures cellular metabolic activity. The key finding, however, was that the combination of ALT and TMZ produced a synergistic reduction in cell viability, an effect greater than the sum of the individual agents.

Beyond simply halting proliferation, the study examined the combination's impact on tumor stemness, a primary driver of GBM's therapeutic resistance and recurrence. The researchers used a sphere formation assay, a functional test that measures the self-renewal capacity of cancer stem cells by their ability to form three-dimensional colonies. The combination treatment synergistically reduced sphere formation, suggesting it effectively targets this resilient cell population. This functional observation was supported by molecular analysis using quantitative polymerase chain reaction (qPCR) and Western blotting, which showed the combination also synergistically reduced the expression of the critical stemness markers CD133, NANOG, and SOX2. For clinicians, targeting these markers is significant because they are hallmarks of the glioblastoma stem-like cells responsible for repopulating tumors after initial treatment.

Impact on Lipid Metabolism and In Vivo Tumor Growth

The investigation also revealed that the combination of alantolactone (ALT) and temozolomide (TMZ) disrupts key metabolic pathways that fuel glioblastoma (GBM) growth. Specifically, the treatment synergistically reduced the expression of the lipid metabolism regulators PLIN2, FASN, and SREBP1. These proteins are vital for cancer cell survival: PLIN2 manages lipid droplet storage, FASN is essential for new fatty acid synthesis, and SREBP1 is a master transcription factor controlling lipid production. Aggressive cancers like GBM often hijack these pathways to generate the building blocks and energy needed for rapid proliferation. By inhibiting these regulators, the combination therapy appears to impair the tumor's ability to sustain its metabolic demands.

Translating these cellular findings into a living system, the xenograft mouse model provided critical validation. In mice bearing human GBM tumors, the combined ALT and TMZ therapy significantly suppressed tumor growth compared to control groups. This demonstrates that the synergy observed in cell culture is potent enough to reduce tumor burden in a complex biological environment. Furthermore, analysis of the tumor tissue revealed that the combined therapy also significantly improved histopathological features. This finding indicates a favorable change in the tumor's microscopic structure, such as reduced cellular density or increased cell death, which are direct indicators of a positive therapeutic response.

Elucidating the Hippo Pathway Mechanism

To define the molecular mechanism behind these effects, the researchers investigated the underlying signaling events. Using phospho-kinase arrays, a screening method that measures the activity of numerous cellular proteins simultaneously, they identified the Hippo pathway as a key mediator. The study found that the alantolactone (ALT) and temozolomide (TMZ) combination promoted YAP1 phosphorylation. YAP1 (Yes-associated protein 1) is an oncogenic transcriptional co-activator; its phosphorylation is the canonical sign of Hippo pathway activation, which sequesters YAP1 in the cytoplasm and prevents it from driving pro-growth gene expression in the nucleus.

This activation of the Hippo tumor suppressor pathway led to important downstream effects. The combination treatment downregulated TEAD2, a transcription factor that partners with YAP1 to initiate gene expression. It also downregulated the oncogenes AXL, a receptor tyrosine kinase linked to drug resistance, and c-MYC, a master regulator of cell proliferation and metabolism. To confirm that the Hippo pathway was truly responsible for the anti-tumor effects, the researchers performed a rescue experiment. They used XMU-MP-1, a known inhibitor of the Hippo pathway, and found that inhibition of Hippo signaling with XMU-MP-1 reversed the anti-tumor effects of the combination treatment. This result provides direct evidence that ALT and TMZ synergistically inhibit GBM by activating the Hippo pathway, which in turn suppresses the expression of genes critical for tumor growth and survival.

Clinical Implications and Future Directions

These preclinical findings provide a compelling rationale for combining alantolactone (ALT) with temozolomide (TMZ) to address the therapeutic resistance and high recurrence rates that define glioblastoma (GBM). The study demonstrates a multi-pronged attack: the combination synergistically reduces cell viability and dismantles the resilient stem-like cell population, evidenced by reduced sphere formation and downregulation of stemness markers (CD133, NANOG, SOX2). Concurrently, it disrupts the tumor's metabolic engine by suppressing key lipid metabolism regulators (PLIN2, FASN, SREBP1). The research mechanistically links these outcomes to the activation of the Hippo tumor suppressor pathway, confirmed by promoted YAP1 phosphorylation and the reversal of anti-tumor effects when the pathway was inhibited.

The synergistic inhibition of GBM growth and stemness, validated in both cell lines and a xenograft mouse model, suggests this combination could overcome some of the biological mechanisms that limit the efficacy of TMZ alone. While these results are encouraging, this remains a preclinical investigation. The necessary next steps include comprehensive pharmacokinetic and safety profiling in more advanced animal models. Should this combination continue to demonstrate a favorable efficacy and safety profile, it could form the basis for future clinical trials, potentially offering a new strategy to improve outcomes for patients with this challenging malignancy.

References

1. Tan AC, Ashley DM, López GY, Malinzak MD, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA A Cancer Journal for Clinicians. 2020. doi:10.3322/caac.21613

2. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020. doi:10.1093/neuonc/noaa106

3. Stupp R, Mason W, Bent MJVD, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005. doi:10.1056/nejmoa043330

4. Meir EGV, Hadjipanayis CG, Norden AD, Shu HG, Wen PY, Olson JJ. Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA A Cancer Journal for Clinicians. 2010. doi:10.3322/caac.20069

5. Wang Y, Feng Y. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.. Clinical neurology and neurosurgery. 2020. doi:10.1016/j.clineuro.2020.105890

6. Ren T, Li Y, Zhou C, et al. Combination of alantolactone and temozolomide targets stemness and lipid metabolism in glioblastoma through YAP1-Hippo signaling.. Brain research. 2026. doi:10.1016/j.brainres.2026.150385

7. Hegi ME, Diserens A, Gorlia T, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine. 2005. doi:10.1056/nejmoa043331

8. Gilbert MR, Wang M, Aldape K, et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology. 2013. doi:10.1200/jco.2013.49.6968

9. Zhao Y, Wu J, Shi L. Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies.. Clinical neuropharmacology. 2021. doi:10.1097/WNF.0000000000000458